#Sleep Apnea

Apnimed Stock Soars 38% in Debut After Upsized US IPO

Sleep-apnea biotech Apnimed's stock jumped 38% in its NYSE debut following an upsized US IPO that exceeded initial targets, underscoring strong investor…

Apnimed IPO Filing Aims to Fund Pivotal Sleep Apnea Drug Study

Apnimed, backed by Japanese drugmaker Shionogi, files IPO to raise capital for Phase 3 trial of oral sleep apnea therapy, targeting a…